YA-104
Schizophrenia
PreclinicalActive
Key Facts
About Yoda Therapeutics
AI‑powered biotech developing disease‑modifying CNS therapies, with a Phase‑II orphan drug candidate for Multiple System Atrophy.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| DB103 (Pomaglumetad) | Denovo Biopharma | Phase 2b/3 |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| RBP-7000 (PERSERIS®) | Indivior | Marketed |
| Undisclosed Programs | Johnson and Johnson Innovative Medicine | Pipeline |
| Schizophrenia Candidate | Teva | Phase 3 |
| Schizophrenia Model Service | NeuroProof | Pre-clinical |
| LYN-005 (Nortiva) | Lyndra | Phase 3 |
| TerXT | Terran Biosciences | Late-stage (Pre-Phase 3) |
| Undisclosed Program | Curemark | Preclinical |
| Schizophrenia Intermediate | OFD Biopharma | Proof of concept |
| Schizophrenia | Keltic Pharma Therapeutics | Pre-clinical |
| AVAT-031 | Avata Biosciences | Discovery |